AstraZeneca’s Fasenra Receives the US FDA’s Approval for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
Shots:
- The US FDA has approved Fasenra (benralizumab) for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults
- The approval was supported by P-III (MANDARA) study assessing the safety & efficacy of Fasenra (single 30mg, SC injection) vs mepolizumab (3 separate 100mg, SC injections, Q4W) to treat r/r EGPA in adults (n=140), in ratio 1:1
- Study demonstrated remission in 60% of patients with 41% vs 26% of them discontinuing oral corticosteroids (OCS); safety & tolerability aligned with known profiles of the drug. Data was published in the NEJM
Ref: AstraZeneca | Image: AstraZeneca
Related News: AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
